Actimmune is a medication that has been approved by the FDA for the treatment of two rare genetic disorders - chronic granulomatous disease (CGD) and severe malignant osteopetrosis (SMO). It is also often used off-label for other conditions, such as idiopathic pulmonary fibrosis and some types of cancer. Actimmune works by boosting the activity of the immune system's white blood cells, which are responsible for fighting off infection and disease. It contains a synthetic version of interferon gamma, a naturally occurring protein that helps regulate the immune response. Dosage and Administration: The recommended dosage of Actimmune varies depending on the indication being treated. For CGD, the usual starting dose is 50 mcg/m2 three times a week. For SMO, the recommended dose is 50 mcg/kg three times per week. In both cases, the dosage may be increased or decreased based on the individual patient's response to treatment. Actimmune is administered subcutaneously, typically by self-injection at home. Patients and caregivers should receive proper training on how to administer the medication before starting treatment. Demographic: Actimmune is approved for use in both adults and children. It is particularly important for patients with CGD and SMO, as these conditions are rare and often require lifelong treatment. It may also be used in off-label settings for other conditions, such as certain types of cancer, but the efficacy and safety of using Actimmune for these indications is still being studied. Side Effects: Like all medications, Actimmune can cause side effects. The most common side effects include flu-like symptoms such as fever, chills, and muscle aches. Injection site reactions, such as redness and swelling, may also occur. More serious side effects are rare, but can include severe allergic reactions and increased risk of infections. Patients taking Actimmune should notify their healthcare provider immediately if they experience any unusual symptoms or side effects. Interactions: Actimmune may interact with other medications the patient is taking. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking before starting Actimmune. Some medications, such as immunosuppressants, may decrease the effectiveness of Actimmune, while others, such as anticoagulants, may increase the risk of bleeding. Generic Options: At this time, there are no generic versions of Actimmune available. The medication is only available in its brand-name form. Patients and caregivers should speak with their healthcare provider and insurance provider to determine the most cost-effective option for obtaining Actimmune. Conclusion: Actimmune is a medication that is approved for use in the treatment of two rare genetic disorders. While it is not a cure, it has been shown to be effective in reducing the frequency and severity of infections in patients with CGD and improving bone density in patients with SMO. It is important for patients and caregivers to receive proper training on how to administer the medication and to report any unusual symptoms or side effects to their healthcare provider.